accountCopyright © thinkBiotech This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. It looks like the ‘new normal’ is not just for biotechnology startups and SME pharma companies – the CROs (and other vendors) who previously benefited from better R&D funding streams also [...] Journal of...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Is the Clinical Research Enterprise in Decline?
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account